Result: S183: Novel combination immunotherapy for the treatment of relapsed/refractory multiple myeloma: updated phase 1b results for talquetamab (A GPRC5D X CD3 bispecific antibody) in combination with daratumumab

*Title*:

*Author/editor-in-chief*:

*Publication*:

Freiburg : Universität, 2024

*Physical description scale*:

1 Online-Ressource

*Format*:

*eBook*

*Language*:

*eng*

*Notes*:

ISSN: 2572-9241

*DOI*:

10.1097/01.hs9.0000843624.82943.92

*Result*: S183: Novel combination immunotherapy for the treatment of relapsed/refractory multiple myeloma: updated phase 1b results for talquetamab (A GPRC5D X CD3 bispecific antibody) in combination with daratumumab